Cargando…

Ridinilazole: a novel, narrow‐spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile

Clostridium (Clostridioides) difficile infection (CDI) remains an urgent threat to patients in health systems worldwide. Recurrent CDI occurs in up to 30% of cases due to sustained dysbiosis of the gut microbiota which normally protects against CDI. Associated costs of initial and recurrent episodes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Collins, Deirdre A, Riley, Thomas V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541751/ https://www.ncbi.nlm.nih.gov/pubmed/35119124 http://dx.doi.org/10.1111/lam.13664

Ejemplares similares

Ridinilazole: a novel antimicrobial for Clostridium difficile infection
por: Cho, Jonathan C., et al.
Publicado: (2019)

Evaluation of the antimicrobial activity of ridinilazole and six comparators against Chinese, Japanese and South Korean strains of Clostridioides difficile
por: Collins, Deirdre A, et al.
Publicado: (2020)

Ridinilazole, a narrow spectrum antibiotic for treatment of Clostridioides difficile infection, enhances preservation of microbiota-dependent bile acids
por: Qian, Xi, et al.
Publicado: (2020)

Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin
por: Thorpe, Cheleste M., et al.
Publicado: (2018)

Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection
por: Bassères, Eugénie, et al.
Publicado: (2016)

Epidemiology of Clostridium difficile infection in Asia
por: Collins, Deirdre A, et al.
Publicado: (2013)

The Novel DNA Binding Mechanism of Ridinilazole, a Precision Clostridiodes difficile Antibiotic
por: Mason, Clive S., et al.
Publicado: (2023)

Clostridium difficile in Asia: Opportunities for One Health Management
por: Collins, Deirdre A., et al.
Publicado: (2018)

1052. Characterisation of the DNA binding properties of ridinilazole, a selective antibiotic currently in phase III trials for the treatment of Clostridioides difficile
por: Mason, Clive, et al.
Publicado: (2021)

A US-based national surveillance study for the susceptibility and epidemiology of Clostridioides difficile isolates with special reference to ridinilazole: 2020–2021
por: Snydman, D. R., et al.
Publicado: (2023)

Clostridioides (Clostridium) difficile Pacemaker Infection
por: Berkefeld, Anna, et al.
Publicado: (2020)

Clostridioides difficile infection in the Asia-Pacific region
por: Collins, Deirdre A., et al.
Publicado: (2019)

1774. Ridinilazole (RDZ) for Clostridium difficile infection (CDI): Correlation of In Vitro Spectrum of Activity with Human Gut Microbiome Profiles from a Phase 2 Clinical Trial
por: Vickers, Richard, et al.
Publicado: (2018)

Spore-Forming Clostridium (Clostridioides) difficile in Wastewater Treatment Plants in Western Australia
por: Chisholm, Jessica M., et al.
Publicado: (2022)

2372. PCR Ribotype and Antimicrobial Susceptibility of Clostridioides (Formerly Clostridium) difficile in Korea
por: Hoo Jeon, Cheon, et al.
Publicado: (2019)

Genotyping and Antimicrobial Susceptibility of Clostridium perfringens and Clostridioides difficile in Camel Minced Meat
por: Fayez, Mahmoud, et al.
Publicado: (2021)

1344. Ridinilazole (RDZ) for Clostridium difficile Infection (CDI): Impact of Diagnostic Method on Outcomes From a Phase 2 Clinical Trial
por: Vickers, Richard, et al.
Publicado: (2018)

1361. Pharmacokinetics and Safety of Ridinilazole (RDZ), a Potential New Therapy for Clostridium difficile Infection (CDI): From Animal Models to Patients
por: Duperchy, Esther, et al.
Publicado: (2018)

Global evolutionary dynamics and resistome analysis of Clostridioides difficile ribotype 017
por: Imwattana, Korakrit, et al.
Publicado: (2022)

Antimicrobial susceptibility of Clostridium difficile isolated in Thailand
por: Putsathit, Papanin, et al.
Publicado: (2017)

A species-wide genetic atlas of antimicrobial resistance in Clostridioides difficile
por: Imwattana, Korakrit, et al.
Publicado: (2021)

Bacteriophages Contribute to Shaping Clostridioides (Clostridium) difficile Species
por: Fortier, Louis-Charles
Publicado: (2018)

Genomic epidemiology and transmission dynamics of recurrent Clostridioides difficile infection in Western Australia
por: Knight, Daniel R., et al.
Publicado: (2023)

668. Quality of Life Changes in Patients with Clostridium difficile Infection (CDI): A Randomized, Double-Blind Trial of Ridinilazole (RDZ) Compared with Vancomycin (VAN)
por: Paul, Sumita, et al.
Publicado: (2019)

Editorial: Microbial interactions of Clostridioides difficile
por: Goh, Shan, et al.
Publicado: (2023)

Toxin profiles and antimicrobial resistance patterns among toxigenic clinical isolates of Clostridioides (Clostridium) difficile
por: Heidari, Hamid, et al.
Publicado: (2019)

Virulence Factors of Clostridioides (Clostridium) difficile Linked to Recurrent Infections
por: Tijerina-Rodríguez, Laura, et al.
Publicado: (2019)

1369. Combined Analysis of the In Vitro Activity of Ridinilazole (RDZ) Against More Than 500 Clostridium difficile (CD) Clinical Isolates and Impact of RDZ on Cell Morphology
por: Duperchy, Esther, et al.
Publicado: (2018)

2387. Selecting Clostridium difficile Infection (CDI) Outcome Measures Relevant to Public Health Concerns: Experience From a Ridinilazole (RDZ) Phase 2 Trial
por: Vickers, Richard, et al.
Publicado: (2018)

Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study
por: Vickers, Richard J, et al.
Publicado: (2017)

Different molecular characteristics and antimicrobial resistance profiles of Clostridium difficile in the Asia-Pacific region
por: Luo, Yun, et al.
Publicado: (2019)

In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) Inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy
por: Dureja, Chetna, et al.
Publicado: (2023)

Novel Antimicrobials for the Treatment of Clostridium difficile Infection
por: Petrosillo, Nicola, et al.
Publicado: (2018)

Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis
por: Sholeh, Mohammad, et al.
Publicado: (2020)

Clostridium difficile ribotype 017 – characterization, evolution and epidemiology of the dominant strain in Asia
por: Imwattana, Korakrit, et al.
Publicado: (2019)

2578. Narrow-Spectrum Antibiotic Treatment of Clostridium difficile Infection Improves Preservation of Intestinal Metabolic Profile
por: Park, Seoyoung, et al.
Publicado: (2019)

Detection, Characterization and Antibiotic Susceptibility of Clostridioides (Clostridium) difficile in Meat Products
por: Muratoglu, Karlo, et al.
Publicado: (2020)

12. Randomized Studies of Two Clostridioides (Clostridium) difficile Vaccine Formulations
por: Lawrence, Jody, et al.
Publicado: (2020)

Clostridioides (Clostridium) difficile in neonatal foals and mares at a referral hospital
por: Weese, Jeffrey Scott, et al.
Publicado: (2021)

COVID-19 and coinfection with Clostridioides ( Clostridium ) difficile in an infant with gastrointestinal manifestation
por: Oba, Jane, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e1mqh8adu4hlulkkqrmkhqrsv8